Free Trial
→ Forget AI Stocks — This Device Will REPLACE the Microchip (From Banyan Hill Publishing) (Ad)tc pixel

Bioventix (LON:BVXP) Sets New 52-Week Low - Here's What Happened

Written by MarketBeat
Updated August 20, 2025
Bioventix logo with Medical background

Key Points

  • Bioventix PLC shares reached a new 52-week low at GBX 2,199 ($29.75) during trading, indicating potential concerns among investors.
  • The company's market capitalization stands at £120.44 million with a price-to-earnings ratio of 14.88 and a relatively low beta of 0.35.
  • Bioventix specializes in sheep monoclonal antibodies for various diagnostic applications, including thyroid and oncology-related testing.
  • Five stocks we like better than Bioventix.

Bioventix PLC (LON:BVXP - Get Free Report)'s share price reached a new 52-week low on Friday . The stock traded as low as GBX 2,199 ($29.59) and last traded at GBX 2,300 ($30.95), with a volume of 12733 shares changing hands. The stock had previously closed at GBX 2,325 ($31.28).

Bioventix Trading Up 4.0%

The firm has a market capitalization of £130.65 million, a PE ratio of 16.14 and a beta of 0.35. The company has a fifty day moving average price of GBX 2,633.29 and a two-hundred day moving average price of GBX 2,709.01.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.

Featured Articles

Should You Invest $1,000 in Bioventix Right Now?

Before you consider Bioventix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.

While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.